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Liver histological improvement after treatment for chronic hepatitis C in patients co-infected with human
immunodeficiency virus-1 (HIV-1) has been described. Paired liver biopsies in twenty six HCV/HIV co-infected
patients were compared to determine factors possibly associated with histological improvement. The patients
were submitted to a liver biopsy before treatment for hepatitis C and 25 months after the end of treatment.
Fragments of the liver biopsy obtained before and after treatment were compared regarding the following
parameters: histological activity index (HAI) and degree of fibrosis (Knodell); intensity of collagen deposits
(Sirius Red staining) and degree of stellate cell activation (alpha-smooth muscle actin labeling). The ratios of the
post and pre-treatment variables were related through logistic regression to body mass index (BMI), alcohol
ingestion, HCV genotype, HCV viremia, presence of hepatic iron and pre-treatment hepatic steatosis. A negative
RNA test in the 24th week of treatment was associated with improvement in fibrosis, collagen deposits and stellate
cell numbers. The other variables analyzed did not correlate to an improvement in hepatic histology after
hepatitis C treatment. Reduction in HCV viremia during treatment may result in reduced hepatic fibrosis even in
patients without a sustained virological response.
Key-Words: Chronic hepatitis C, hepatic stellate cell, histological response, human immunodeficiency virus, paired
liver biopsies.
It is known that human immunodeficiency virus (HIV) may
modify the natural history of hepatitis C virus infection (HCV)
by accelerating the progression of hepatic fibrosis and its
complications, especially in severely immunocompromised
patients [1-3]. PEGylated or non-PEGylated interferon-alpha
in combination with ribavirin, the recommended treatment for
chronic hepatitis C, can promote a sustained virological
response (SVR) in a considerable number of patients and, in
some cases reduce the liver inflammatory and fibrotic processes
[4,5]. In addition, some studies have shown that treatment
with interferon-alpha leads to improved liver histology, mainly
reducing inflammation and having a lesser effect on fibrosis
[6], especially in patients who show a sustained virological
response [7,8]. On the other hand, the influence of the
treatment on the improvement of hepatic histology in patients
who do not have SVR has shown controversial results [9-13].
Progression of hepatic fibrosis has been associated in
HCV/HIV co-infected patients with some factors like gender
(males), more advanced age when HCV infected, higher alcohol
ingestion, lymphocytes CD4
+ cells < 500/mm3 and HAART
non-users [14,15]. In mono-infected patients, iron overload
and hepatic steatosis may also be associated with a rapid
fibrotic progression [16,17].
The objective of the present study was to evaluate factors
possibly associated with improvement in liver histology after the
treatment of chronic hepatitis C in patients co-infected with HIV.
Material and Methods
Patients
Twenty six adult patients (19 males) with chronic hepatitis
C co-infected with HIV-1 were included in the study.
The inclusion criteria were, to be older than 18 years, to
have confirmed HCV and HIV infections, to have been in
treatment for chronic hepatitis C for at least 24 weeks and to
accept participation in the study by signing the informed
consent form. The exclusion criteria were, to have other
associated hepatic diseases, to be infected with hepatitis B
virus, to have any active opportunistic disease and to present
any contraindication for a liver biopsy or for treatment of
hepatitis C. The study was approved by the Ethics Committee
of the University Hospital, Faculty of Medicine of Ribeirao
Preto, University of Sao Paulo, Brazil.
Table 1 shows the general, demographic virological and
histological characteristics of the patients included in the
study, obtained before hepatitis C treatment.
Treatment of Chronic HCV Infection
Patients were treated, in standard regimens, with interferon-
alpha and ribavirin (RBV) in 70% of cases, with PEGylated
interferon-alpha and RBV in 25% of cases and with interferon-
alpha monotherapy in 5% of the patients over a mean period
of 34.4 ±9.03 weeks.
HCV RNA
HCV RNA was determined by a qualitative test, having an
inferior limit of detection of 50 copies/mL (COBAS
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AMPLICOR®, Roche Diagnostics GmbH, Mannheim,
Germany), carried out before the beginning of treatment and,
afterwards, in the 24th week, in the 48th week and 6 months
after the end of treatment (72nd week). A negative HCV RNA
by the 72nd week was considered as a sustained virological
response (SVR).
Histological Evaluation
Patients were submitted to an ultrasound-guided
percutaneous liver biopsy with a 14 G Tru-Cut needle under
local anesthesia before the beginning of treatment and about
25 months after the end of treatment for hepatitis C. Liver
histology and immunohistochemical analysis were carried out
by two independent pathologists in a blinded fashion. Fibrosis
degree and the histological activity index (HAI) were assessed
according to the classification of Knodell et al. modified by
Table 1. Baseline characteristics of patients (n=26) with chronic hepatitis C co-infected with HIV.
Desmet et al. [18]. Semi quantitative analysis of collagen
deposition was performed by Sirius Red staining, using a point-
counting procedure at 400x magnification. A total of 1,000 points
per liver were counted for each patient and each point was
classified as positive or negative for collagen. The results were
reported as percentage of points stained by Sirius Red [19].
Histological semi quantitative analysis of iron deposits
was made by Perl’s staining according to the classification by
Sciot et al. [20]. The grade of hepatic steatosis was evaluated
by the method of Patton et al. [21].
Hepatic stellate cells (HSC) were evaluated by
immunohistochemical staining for α-smooth muscle actin (α-
SMA, 1A 4, DAKO A/S, Denmark, 1:100 dilution), using an
avidin-biotin-peroxidase complex system (Novostain Super
ABC Kit, Universal, Novocastra Laboratories Ltd., UK),
counterstaining with hematoxylin and by comparison with
Characteristics N
Male (%) 19.0  (73.0)
Age (years) mean (SD) 37.3 (5.3)
Body-mass index (kg/m2) mean (SD) 24.2 (4.0)
Use of antiretroviral drugs, no (%) 22.0 (84.6)
CD4
+T lymphocytes in blood, mean (SD) 687.5 (254.8)
200 - 500 cells/µL no (%) 4.0 (15.3)
≥ 500 cells/µL no (%) 22.0 (84.7)
HIV RNA
≤50 copies/mL no (%) 10.0 (41.7)
>50 copies/mL no (%) 14.0 (58.3)
Log10 of HIV RNA, mean (SD) 3.8 (0.7)
HCV Genotype 1 no (%) 21.0 (80.8)
Genotype 2 1.0 (3.8)
Genotype 3 4.0 (15.4)
Histological parameters of liver biopsies
HAI no (%) 1-3 (minimal) 0.0 (0)
4-8 (mild) 8.0 (30.8)
9-12 (moderate) 17.0 (65.4)
13-18 (severe) 1.0 (3.8)
Fibrosis no (%) F0 (absent) 0.0 (0)
F1 (mild) 8.0 (30.8)
F2 (moderate) 17.0 (65.4)
F3 (severe) 1.0 (3.8)
F4 (cirrhosis) 0.0 (0)
Collagen deposits, mean (SD) 26.2 (9.3)
Number of HSC alpha-SMA positive per field, mean (SD) 24.7 (7.8)
Iron deposits no (%) Absent 15.0 (57.7)
Present 11.0 (42.3)
Steatosis no (%) Absent 10.0 (38.5)
Present 16.0 (61.5)
ALT no (%) ≥ 2 ULN 13.0 (50.0)
< 2 ULN 13.0 (50.0)
HSC alpha-SMA=hepatic stellate cells positive for smooth muscle alpha actin; HAI=histological
activity index; ALT=alanine aminotransferase; ULN=upper limit of normality.
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positive and negative controls. The number of α-SMA-
positive cells per microscopic field was evaluated, blindly,
at high power (400x) magnification in 10 fields chosen at
random [22].
Paired Analysis of the Biopsies
The parameters were expressed numerically as follows:
for HAI and fibrosis, scores of 1 to 18 and from 0 to 4,
respectively. Collagen deposit was expressed as percentage
of points stained by Sirius Red and HSC, as the number of
alpha-SMA-positive cells per microscopic field. Histological
improvement, evaluated separately for each parameter, was
considered when the numerical ratio of results obtained for
the paired biopsies (post-/pre-treatment) was 1 or less.
Statistical Analysis
A model of logistic regression was used to analyze the
association of liver histological improvement with the following
independent variables: body mass index (BMI, < or ≥ 25 kg/
cm2); alcohol ingestion (yes/no); HCV genotype (1/non-1);
RNA HCV at the 24th week after the beginning of treatment
(positive/negative); hepatic iron in the pre-treatment biopsy
(positive/negative); hepatic steatosis in the pre-treatment
biopsy (absent/present) and the pre-treatment alanine
aminotransferase (ALT) values (< or ≥ twice the upper limit of
normality (ULN). The dependent, response variables, were
the fibrosis grade, the HAI index, the grade of collagen
deposits and the number of HSC-α-SMA positive cells.
Results were expressed as odds-ratios (OR), with the
respective 95% confidence intervals (CI).
Results
The analyses of associations of the independent variables
with the improvement of fibrosis, HAI, collagen deposits and
number of HSC-α-SMA positive cells in paired biopsies, before
and after hepatitis C treatment are summarized in Tables 2-5.
In relation to HAI there was no association between
variables and improvement of this histological parameter
(Table 2). On the other hand, there was an association
between the variable RNA HCV negative at the 24th week of
treatment and improvement in fibrosis (OR, 11.94; CI,
11.41:...), collagen deposition (OR 11.48; CI, 1.024-214.86)
and the grade of activated hepatic stellate cells (OR, 11.48;CI,
1.044- 214.86).
Discussion
Sustained virological response (SVR) has been obtained
in about 50% of patients after treatment for chronic hepatitis
C depending on the type of treatment employed and the HCV
genotype [4]. Lower rates of SVR are obtained in patients co-
infected with HIV [24,25], indicating that a high percentage of
these patients continue to be at risk of developing cirrhosis
and its complications. Thus, analysis of histological evolution
in these patients, especially in those without SVR, is important
for a better understanding of the disease course.
 In the present study, a negative HCV RNA at the 24th
week of treatment was related to improvement in fibrosis and
collagen deposits and to reduced activation of hepatic stellate
cells. This means that viremia control during treatment might
be determinant in reducing disease progression, even in HCV/
HIV co-infected individuals. It is interesting to note, however,
that while the histological improvement was observed in 4
SVR patients, it was also present in three patients who did not
show a sustained virological response (data not shown).
There are few studies on the course of hepatic histology
after treatment for hepatitis C in patients co-infected with
HIV. In some of these, non-responders to treatment with
interferon-alpha also had histological improvement or
stabilization of fibrosis after treatment [25,26]. Association
of virological and histological responses in HCV/HIV co-
infected patients was also observed by Lissen et al. [27].
These authors reported improvements in hepatic histology
in 62% to 74% of SVR patients and in 32% to 43% of non-
responders, according to the type of treatment they used.
Liver histology, evaluated by means of paired biopsies in
HCV mono-infected patients, demonstrated an improvement
in necroinflammation and even in fibrosis in those presenting
SVR [7,8,13]. Stabilization of fibrosis has also been observed
in non-responder patients after treatment with interferon-alpha
[28], a fact that could be indicative of histological response
since progression of fibrosis is expected to be the natural
course of chronic hepatitis. Histological improvement was
also observed in non-responders, even in the patients
presenting a reduction of HCV viremia during treatment [29].
Physiopathological mechanisms implicated in the
progression of hepatic fibrosis during chronic HCV infection
are multiple, but HSC (perisinusoidal cells, Ito cells or fat-
storing cells) activation is known to play a key role in the
pathogenesis of hepatic fibrosis [30,31]. Under the action of
mediators released by the inflammatory process in the liver,
HSCs undergo activation and trans-differentiation to a
“myofibroblast-like” phenotype, which express membrane a-
SMA. These cells loose the ability to store retinoids, proliferate
vigorously and proceed to contract and produce cytokines
[32], which result in the increased production and degradation
of the extracellular matrix, originating collagen and adhesive
proteoglycans and glycoproteins. Increased fibrosis and,
consequently, evolution to cirrhosis, are the final steps of
these phenotypic and functional changes [33].
HSC were also evaluated in paired biopsies, obtained before
and after treatment in mono-infected patients. Sakaida et al. [34],
observed an association between a reduction in the number of
these activated cells and an improvement in fibrosis, both in patients
presenting and not presenting sustained virological responses.
The present study suggests that the control of HCV viremia
during treatment of hepatitis C can modify the natural history
of the chronic disease in patients co-infected with HIV and
this beneficial effect is accompanied by the reduced activation
of HSC cells. However, the long-term benefit of this histological
improvement will need further evaluation.
Treatment in Patients with HIV/HCV Co-Infection
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Table 2. Analysis of variable values associated to HAI results (Improved and Not improved) in paired biopsies, taken before and
after chronic hepatitis treatment in patients co-infected with HIV. Results of logistic regression (OR).
Table 3. Analysis of variable values associated to results of fibrosis (Improved and Not improved) in paired biopsies, taken
before and after chronic hepatitis C treatment in patients co-infected with HIV. Results of logistic regression (OR).
Treatment in Patients with HIV/HCV Co-Infection
Variables HAI OR (CI 95%)
Improved Not Improved
BMI
< 25 9 (81.8) 10 (66.7)
≥ 25 2 (18.2) 5 (33.3) 0.45 (0.03; 3.73)
Alcohol ingestion
No 1 (9.1) 4 (26.7)
Yes 10 (90.9) 11 (73.3) 3.47 (0.28; 196.66)
HCV genotype
Non-1 2 (18.2) 3 (20.0)
1 9 (81.8) 12 (80.0) 1.12 (0.10; 16.09)
RNA HCV (24th week)
Positive 5 (45.5) 8 (88.9)
Negative 6 (54.5) 1 (11.1) 8.53 (0.71; 495.38)
Iron (pre-treatment)
Absent 7 (63.6) 8 (53.3)
Present 4 (36.4) 7 (46.7) 0.66 (0.09; 4.11)
Steatosis (pre-treatment)
Absent 3 (27.3) 7 (46.7)
Present 8 (72.7) 8 (53.3) 2.26 (0.34; 18.61)
ALT (pre-treatment)
< 2 ULN 4 (36.4) 9 (60.0)
≥ 2 ULN 7 (63.6) 6 (40.0) 2.53 (0.41; 17.79)
HAI=histological activity index; BMI=body mass index; ALT=alanine aminotransferase; ULN=.upper limit of normality.
Variables Fibrosis OR (CI 95%)
Improved Not improved
BMI
< 25 13 (86.7) 6 (54.6)
³ 25 2 (13.3) 5 (45.4) 0.198 (0.01; 1.64)
Alcohol ingestion
No 2 (13.3) 3 (27.3)
Yes 13 (86.7) 8 (72.7) 2.352 (0.22; 34.07)
HCV genotype
Not1 3 (20.0) 2 (18.2)
1 12 (80.0) 9 (81.8) 0.893 (0.06; 9.63)
RNA HCV (24
th
 week)
Positive 5 (41.7) 8 (100.0)
Negative 7 (58.3) 0 (0.0) 11.936 (1.41;...)
Iron (pre-treatment)
Absent 9 (60.0) 6 (54.6)
Present 6 (40.0) 5 (45.4) 0.807 (0.13; 5.09)
Steatosis (pre-treatment)
Absent 5 (33.3) 5 (45.4)
Present 10 (66.7) 6 (54.6) 1.634 (0.25; 10.89)
 ALT (pre-treatment)
< 2 ULN 7 (46.7) 6 (54.6)
³ 2 ULN 8 (53.3) 5 (45.4) 1.355 (0.22; 8.59)
BMI=body mass index; ALT=alanine aminotransferase; ULN=upper limit of normality.
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Table 4. Analysis of variable values associated to results of collagen deposits (Improved and Not improved) in paired biopsies,
taken before and after chronic hepatitis C treatment in patients co-infected with HIV. Results of logistic regression (OR).
Table 5. Analysis of variable values associated to the results of HSC activation (Improved and Not improved) in paired biopsies,
taken before and after chronic hepatitis C treatment of patients co-infected with HIV. Results of logistic regression (OR),
Treatment in Patients with HIV/HCV Co-Infection
Variables                HSC activation OR (CI 95%)
Improved Not improved
BMI
< 25 8(100.0) 11 (61.1)
³ 25 0 (0.0) 7 (38.9) 0.16 (0; 1.33)
Alcohol ingestion
No 2 (25.0) 3 (16.7)
Yes 6 (75.0) 15 (83.3) 0.61 (0.05; 9.08)
HCV genotype
Not1 2 (25.0) 3 (16.7)
1 6 (75.0) 15 (83.3) 0.61 (0.05; 9.08)
RNA HCV (24
th
 week)
Positive 2 (28.6) 11 (84.6)
Negative 5 (71.4) 2 (15.4) 11.48 (1.04; 214.86)
Iron (pre-treatment)
Absent 5 (62.5) 10 (55.6)
Present 3 (37.5) 8 (44.4) 0.76 (0.09; 5.42)
Steatosis (pre-treatment)
Absent 1 (12.5) 9 (50.0)
Present 7 (87.5) 9 (50.0) 6.53 (0.62; 349.80)
ALT (pre-treatment)
< 2 ULN 4 (50.0) 9 (50.0)
³ 2 ULN 4 (50.0) 9 (50.0) 1.00 (0.14; 7.28)
HSC, hepatic stellate cells; BMI, Body Mass Index; ALT, alanine aminotransferase; ULN, upper limit of normality.
Variables             Collagen deposit OR (CI 95%)
Improved Not improved
BMI
< 25 7 (100.0) 12 (63.2)
³ 25 0 (0.0) 7 (36.8) 0.205 (...; 1.68)
Alcohol ingestion
No 1 (14.3) 4 (21.1)
Yes 6 (85.7) 15 (78.9) 1.573 (0.12; 91.75)
HCV genotype
Not1 2 (28.6) 3 (15.8)
1 5 (71.4) 16 (84.2) 0.484 (0.04; 7.34)
RNA HCV (24
th
 week)
Positive 2 (28.6) 11 (84.6)
Negative 5 (71.4) 2 (15.4) 11.480 (1.04; 214.86)
Iron (pre-treatment)
Absent 5 (71.4) 10 (52.6)
Present 2 (28.6) 9 (47.4) 0.458 (0.03; 3.73)
Steatosis (pre-treatment)
Absent 1 (14.3) 9 (47.4)
Present 6 (85.7) 10 (52.6) 5.094 (0.47; 275.43)
ALT (pre-treatment)
< 2 ULN 3 (42.9) 10 (52.6)
³ 2 ULN 4 (57.1) 9 (47.4) 1.459 (0.18; 12.85)
BMI, Body mass index; ALT, alanine aminotransferase; ULN, upper limit of normality.
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